A Single-arm, Open-label, Multicenter Phase 3 Study of the Contraceptive Efficacy, Safety and Tolerability of the AG200-15 Transdermal Contraceptive Delivery System (TCDS)

Trial Profile

A Single-arm, Open-label, Multicenter Phase 3 Study of the Contraceptive Efficacy, Safety and Tolerability of the AG200-15 Transdermal Contraceptive Delivery System (TCDS)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary)
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Acronyms SECURE
  • Sponsors Agile Therapeutics
  • Most Recent Events

    • 16 Oct 2017 Results presented at the 2017 National Association for Family Planning (NAFFP), "The Forum", according to an Agile Therapeutics media release.
    • 28 Sep 2017 According to an Agile Therapeutics media release, data from the study will be presented as a poster presentation during the North American Forum on Family Planning Annual Meeting 2017.
    • 07 Sep 2017 According to an Agile Therapeutics media release, additional data from this study will be presented during the American Society for Reproductive Medicine (ASRM) Annual Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top